Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

24.72
+1.697.34%
Post-market: 25.200.4800+1.94%19:59 EST
Volume:1.13M
Turnover:27.95M
Market Cap:1.28B
PE:-13.69
High:25.21
Open:23.36
Low:23.23
Close:23.03
52wk High:40.37
52wk Low:4.30
Shares:51.72M
Float Shares:46.19M
Volume Ratio:1.13
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8055
EPS(LYR):-1.1490
ROE:-107.79%
ROA:-49.39%
PB:15.24
PE(LYR):-21.51

Loading ...

Capricor Therapeutics stellt neue Pipeline-Strategien und Fortschritte bei Duchenne-Muskeldystrophie-Therapien vor

Reuters
·
Feb 05

FDA Requests Additional HOPE-3 Data for Capricor's Deramiocel Approval Review

Reuters
·
Jan 20

Capricor Therapeutics Inc - FDA Requests Hope-3 Clinical Study Report for Bla Review

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc: FDA Did Not Request Any Additional Clinical Studies or New Patient Data as Part of This Request

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc - FDA Requests Full Hope-3 Report to Address Crl

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc - Expects to Submit Bla Updates in February 2026

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics: HOPE-3 Success, De-Risked Regulatory Path, and Priority Review Voucher Upside Support Buy Rating

TIPRANKS
·
Jan 20

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals

Simply Wall St.
·
Jan 13

Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal

Simply Wall St.
·
Jan 10

Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal

Simply Wall St.
·
Dec 22, 2025

Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Duchenne Muscular Dystrophy Therapy

Reuters
·
Dec 17, 2025

Capricor Therapeutics Price Target Raised to $50.00/Share From $21.00 by B. Riley Securities

Dow Jones
·
Dec 16, 2025

Capricor Therapeutics Inc : B. Riley Raises Target Price to $50 From $21

THOMSON REUTERS
·
Dec 15, 2025

B. Riley Adjusts Price Target on Capricor Therapeutics to $50 From $21, Maintains Buy Rating

MT Newswires Live
·
Dec 15, 2025

Capricor Therapeutics Price Target Raised to $45.00/Share From $20.00 by Piper Sandler

Dow Jones
·
Dec 11, 2025

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10, 2025

Capricor Therapeutics Shares Climb as Analysts Project Profitability by 2028

Dow Jones
·
Dec 09, 2025

Oppenheimer Adjusts Capricor Therapeutics PT to $54 From $22, Maintains Outperform Rating

MT Newswires Live
·
Dec 08, 2025

Capricor Therapeutics Inc. : Oppenheimer Raises Target Price to $54 From $22

THOMSON REUTERS
·
Dec 08, 2025

Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes

Benzinga_recent_news
·
Dec 08, 2025